ArticleStem cell research & therapy2026
A noncanonical neuroligin 3-centered complex promotes functional recovery of spinal cord injury.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundWhile human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) hold great potential for spinal cord injury (SCI) treatment, their intrinsic mechanisms are not fully understood. Given their multipotency, especially their neuronal transdifferentiation potential, we hypothesized that investigating the in situ transcriptional reprogramming of transplanted hUC-MSCs within the spinal cord microenvironment (SCE) could shed light on crucial genes for SCI repair.
methodsDiD-labeled hUC-MSCs were intrathecally transplanted in rats with or without sub-acute spinal cord bilateral hemisection injury and subsequently retrieved for RNA-seq. Comparative analysis of the transcriptomes of hUC-MSCs and functional screenings in vitro and in vivo, including heterologous synapse formation assay, transplantation of MSCs with gene overexpression or knockdown, AAV-mediated neuron-specific gene expression in SCI rats, behavioral tests, and motor evoked potentials (MEPs) were performed to identify the novel target gene Neuroligin 3 (Nlgn3). Immunoprecipitation followed by mass spectrometry (IP-Mass spec), cell aggregation assay, and immuno-electron microscopy were used to reveal the functional interacting partners of Nlgn3. Moreover, RT-qPCR, western blotting, immunofluorescence staining, and co-IP were used to elucidate the underlying mechanism.
resultsUsing RNA-seq and functional screening, we identified NLGN3 as a neuronal cell adhesion molecule (CAM) activated by the SCE in transplanted hUC-MSCs to promote therapeutic efficacy. Critically, the neuron-specific restoration of Nlgn3 in the injured spinal cord alone was sufficient to achieve a comparable therapeutic effect. Mechanistically, Nlgn3 recruits the synaptic vesicle proteins Sar1a and Hspa8 to modulate synaptic strength. The combinatorial restoration of Nlgn3 with either Sar1a or Hspa8 synergistically enhanced SCI repair, highlighting the functional importance of this noncanonical Nlgn3-Sar1a-Hspa8 axis.
conclusionsThis work unveils a novel therapeutic role for Nlgn3 in SCI treatment, demonstrating its ability to both enhance MSC transplantation efficacy and directly promote neural circuit reconstruction. We also propose a combinatorial strategy of targeting the noncanonical Nlgn3-centered protein complex. Furthermore, our study provides a valuable framework for uncovering novel therapeutic targets by investigating the transcriptional reprogramming of transplanted MSCs within injury microenvironments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.